The ADC has several studies under way and we are looking for volunteers to help us learn more about memory loss. To volunteer, leave your contact information on the Join a Study page.
To learn more about studies under way, scroll down for more information or call the UT Southwestern Memory Research Unit at 214-648-0563.
Study participants like Dewayne Nash, M.D., (see video below) have found that participating in our clinical trials has helped him in ways he never expected.
Observational and Biomarker Development Studies
LOAD (Late Onset Alzheimer’s Disease) Study
This study is being done to help researchers learn more about risk factors which might be associated with the development of diseases of the nervous system associated with late-onset Alzheimer’s disease (late onset is defined as symptoms of AD beginning at age 60 or older), aging, and other related disorders. Other related disorders may include early-onset Alzheimer’s disease, frontotemporal degeneration, lewy body dementia, corticobasal degeneration, and progressive supranuclear palsy.
Participants will have a neurological examination, a blood draw, and take cognitive (memory and thinking) tests. The LOAD study requires you to have a reliable Study Partner (someone who knows you really well) in order for you to participate. You may be asked to return annually for up to 5 years to repeat the same testing. If you are 50 years and older, have been diagnosed with AD, and are interested in participating in this study, please call Amy Browning at 214-645-1972.
ADNI3 – Alzheimer’s Disease Neuroimaging Initiative 3
The goal of this study is to look at the relationship between clinical, cognitive, imaging, genetic, and biomarker tests to understand the full spectrum of Alzheimer’s disease from its earliest stages. The data from this research study will be used in the development of future research studies that will focus on the treatment of AD at an early stage.
We will collect data from cognitive tests, brain MRI scans, blood draw, PET scans and cerebral spinal fluid tests (Lumbar Punctures are optional). The ADNI3 study requires you to have a reliable Study Partner in order for you to participate. It will require two to four separate visits to our clinic in order to complete all of the testing. You may be asked to return in one year to repeat the same testing. Your participation could last up to 5 years. If you are between 55 and 90 years old, are cognitively normal, or have been diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer’s Disease, and are interested in participating in this study, please call Amy Browning at 214-645-1972.
A4 – Anti-Amyloid Treatment In Asymptomatic AD
The A4 study is for individuals aged 65-85 who have normal thinking and memory function but who have evidence of amyloid plaque build-up in their brains and who may be at risk for developing Alzheimer's disease (AD) memory loss in the future. A4 is a ground-breaking trial that will test an anti-amyloid investigational drug in older individuals who do not yet show symptoms of Alzheimer's disease cognitive impairment or dementia with the aim of delaying or preventing memory and cognitive decline. Please call Erica Adkins, 214-648-9343, for more details.
ARTFL – Advancing Research and Treatment for Frontotemporal Lobar Degeneration (FTD): Research Projects 1 & 2
The goal of this study is to collect data from cognitive tests, brain MRI scans, blood tests, and cerebral spinal fluid tests (Lumbar Punctures are optional) to support the development of FTD therapies for new clinical trials. Participants will have their blood tested for the presence of FTD-associated genes; this information will be compared to the neurological and cognitive data that is collected to help design potential new therapies. The ARTFL study is a Registry Study and requires you to have a reliable Study Partner for you to be eligible to participate. It will require two to four visits to our clinic to complete the testing. You may be asked to return in one year to repeat testing. If you are between the ages of 18 and 85, have been diagnosed with FTD, and are interested in participating in this study, please call Jana Windsor at 214-648-9118.
AVID-A19 – 18F-AV-1451 PET Imaging in Subjects with Frontotemporal Dementia
In order to participate in this PET imaging study, you must first qualify for, and be enrolled in, the ARTFL study.
This is a Phase I clinical trial that will evaluate the imaging characteristics of 18F-AV-1451 in subjects with Frontotemporal Dementia (FTD). 18F-AV-1451 has been developed as a Positron Emission Tomography (PET) Scan imaging agent that identifies the presence of tau protein aggregates. 18F-AV-1451 may be a useful marker of tau pathology in patients with AD and other neurodegenerative disorders. The purpose of the current study is to extend preliminary findings by evaluating the usefulness of AV-1451 in FTD and, in particular, whether the regional pattern of tau deposition typical of AD is present in FTD cases. The AVID-A19 study is an imaging study that requires a brain MRI and either one or two brain PET Scans. If you are 18 or older, can tolerate MRI & PET Scans, and are interested in participating in both ARTFL and AVID-A19, please call Jana Windsor at 214-648-9118.